SAN FRANCISCO—Harmon Cyrus, a director at Olema Prescription drugs, Inc. (NASDAQ:OLMA), a $493.56 million market cap biotech firm, lately executed a collection of inventory transactions, based on a submitting with the Securities and Change Fee. The transactions come as InvestingPro information reveals the inventory has skilled important volatility, falling 18% prior to now week. On December 9, Cyrus acquired 29,250 shares of frequent inventory with none financial change, as these shares have been a part of a performance-based restricted inventory unit award that vested upon assembly particular firm milestones.
On December 10 and 11, Cyrus offered a complete of 16,393 shares of Olema Prescription drugs inventory. These gross sales have been primarily carried out to cowl tax obligations associated to the vesting of the performance-based inventory models. The transactions have been executed at costs starting from $8.66 to $9.39 per share, leading to a complete worth of roughly $147,955.
Following these transactions, Cyrus holds 764,140 shares instantly and an extra 122,028 shares not directly by way of the Harmon Household Traders LLC.
In different latest information, Olema Prescription drugs has been making notable strides with a number of important developments. H.C. Wainwright reaffirmed a Purchase score for Olema, following the presentation of preclinical information for the corporate’s KAT6 inhibitor, OP-3136, on the EORTC-NCI-AACR Symposium. The info confirmed elevated inhibition of T47D breast most cancers cells when OP-3136 was mixed with different most cancers medicine, significantly ribociclib.
The corporate additionally offered promising information from its Section 1b/2 examine of palazestrant mixed with ribociclib for treating ER+/HER2- metastatic breast most cancers. The examine, which has enrolled 62 sufferers, confirmed that palazestrant didn’t have an effect on ribociclib publicity, a major discovering as different oral Selective Estrogen Receptor Degraders (SERDs) have required dosage changes when used with CDK4/6 inhibitors.
TD Cowen reiterated a Purchase score, inspired by the Medical Profit Fee of 78-79% from a Section II trial involving palbociclib and ribociclib. Jefferies additionally maintained a Purchase score, highlighting the potential of the corporate’s KAT6 inhibitor, OP-3136. The agency expects OP-3136 to enter Section 1 trials in early 2025.
Goldman Sachs maintained its Purchase score on Olema Prescription drugs, following the presentation of preclinical information for OP-3136 on the EORTC-NCI-AACR Symposium. The research demonstrated OP-3136’s anti-tumor exercise, displaying additional enchancment when used with endocrine remedy and CDK4/6 inhibitors. These are latest developments shaping the investor sentiment round Olema Prescription drugs.
This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.
